Researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated how trochlear anatomy evolves during pediatric development with and without recurrent patellofemoral instability (PFI), a condition where the kneecap repeatedly slips out of its groove, causing pain, swelling and difficulty with physical activity. The findings, recently reported in a landmark study in the American Journal of Sports Medicine, highlighted that PFI in growing children worsens trochlear dysplasia, which can result in further kneecap instability, while those without PFI experienced natural improvements.

In a landmark translational study, collaborators identified the specific milk protein that triggered a patient’s case of eosinophilic esophagitis

Heart transplant policies underwent significant changes in 2016 and 2018, altering how hearts are allocated to patients waiting for a transplant. These changes aimed to improve survival rates and outcomes for patients on the transplant waitlist by prioritizing those with the most pressing needs. In a recent study in Circulation, researchers at Children’s Hospital of Philadelphia (CHOP) reviewed the outcomes and found some patient groups benefitted from the allocation updates, while others did not experience the same level of improvement.

CHOP’s Celiac Center hosted the Beyond Celiac Research Summit recently, detailing the latest celiac research and best practices in long-term treatment

In a preclinical study, researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated a novel treatment strategy for patients with Fanconi anemia (FA), a rare genetic disease resulting in loss of blood-forming stem cells in the bone marrow. The researchers successfully used in situ mRNA delivered directly into the body by lipid nanoparticles (LNPs) to target bone marrow cells and transiently restore stem cell function in patients with FA.

Preclinical study suggests immunotherapies targeting mitochondria could treat certain tumors.

CHOP is recruiting research participants for a new observational study called, “DISCOVERY of Risk Factors for Type 2 Diabetes in Youth,” led by Lorraine L. Katz, MD.

Tzield, the first FDA-approved treatment to delay the onset of clinical diabetes, is now available in the Type 1 Diabetes clinic at CHOP

Learn more about how genetic testing offers the best means of distinguishing between the focal and diffuse forms of HI in children.

Aimee Ortega describes her thoughts participating in the Global Health Allies Program in the Dominican Republic.